Market closed
Reviva Pharmaceuticals/$RVPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Ticker
$RVPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
14
Website
RVPH Metrics
BasicAdvanced
$35M
-
-$0.90
0.05
-
Price and volume
Market cap
$35M
Beta
0.05
52-week high
$3.42
52-week low
$0.49
Average daily volume
862K
Financial strength
Current ratio
1.006
Quick ratio
0.923
Total debt to equity
56.383
Interest coverage (TTM)
-1,673.77%
Management effectiveness
Return on assets (TTM)
-98.20%
Return on equity (TTM)
-916.17%
Valuation
Price to book
43.22
Price to tangible book (TTM)
43.22
Price to free cash flow (TTM)
-0.745
Growth
Earnings per share change (TTM)
-45.29%
3-year earnings per share growth (CAGR)
16.14%
What the Analysts think about RVPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Reviva Pharmaceuticals stock.
RVPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RVPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RVPH News
AllArticlesVideos
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
GlobeNewsWire·3 weeks ago
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewsWire·2 months ago
Reviva to Participate in the 2025 BIO CEO & Investor Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Reviva Pharmaceuticals stock?
Reviva Pharmaceuticals (RVPH) has a market cap of $35M as of April 17, 2025.
What is the P/E ratio for Reviva Pharmaceuticals stock?
The price to earnings (P/E) ratio for Reviva Pharmaceuticals (RVPH) stock is 0 as of April 17, 2025.
Does Reviva Pharmaceuticals stock pay dividends?
No, Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Reviva Pharmaceuticals dividend payment date?
Reviva Pharmaceuticals (RVPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Reviva Pharmaceuticals?
Reviva Pharmaceuticals (RVPH) has a beta rating of 0.05. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.